This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Immunization  • Drug Therapy  • Adverse Effects  • Medication Error  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

JAMA. 2006;296:2082-2083.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2006;55:1016-1017

1 table omitted

During June-August 2005, CDC and the Food and Drug Administration (FDA) were notified of seven clusters of inadvertent subcutaneous (SC) misadministration of the new meningococcal conjugate vaccine (MCV4, Menactra) (Sanofi Pasteur, Inc., Swiftwater, Pennsylvania), which is licensed for intramuscular (IM) administration only. A total of 101 persons in seven states were reported to have received MCV4 by the SC route. Of these, 100 were contacted by their health-care providers and advised of the administration error. CDC conducted an investigation to determine whether SC administration of MCV4 resulted in a protective immunologic response. This report describes the results of that investigation, which indicated that, despite the misadministration, persons vaccinated by the SC route were sufficiently protected and that revaccination was not necessary.

In 1978, the meningococcal polysaccharide vaccine (MPSV4, Menomune) (Sanofi Pasteur) was licensed in the United States for administration by the SC route. The newer . . . [Full Text of this Article]

Reported by:



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?